FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental cancer drug met the main goal of a late-stage study.

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset ...

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs. Now a team of researchers have discovered that this workhorse protein, called cereblon, in ...

Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...